Central nervous system toxicity induced by irinotecan

Journal of the National Cancer Institute

Volumn 98, Issue 3, 2006, Pages 219-

  Hamberg, Paul ^a,b   Donders, Richard C J M ^a   ten Bokkel Huinink, Daan ^a  

^a DEPARTMENT OF SURGERY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ATROPINE; CAMPTOTHECIN; CAPECITABINE; DEXAMETHASONE; GRANISETRON; IBUPROFEN; IRINOTECAN; PARACETAMOL;

ADULT; ATAXIA; CASE REPORT; CENTRAL NERVOUS SYSTEM; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; HUMAN; LETTER; LIVER METASTASIS; MALE; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PRIORITY JOURNAL; SIGMOID CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CENTRAL NERVOUS SYSTEM; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SIGMOID NEOPLASMS; TACHYPHYLAXIS;

EID: 32144436085     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djj034     Document Type: Letter

References (7)

1. Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. Semin Oncol 1999;26(suppl 5):6-12.
2. Sevilla Garcia I, Rueda A, Alba E. Irinotecan-induced central nervous system toxicity: A case report. J Natl Cancer Inst 1999;91:647.
3. Baz DV, Bofill JS, Nogueira JA. Irinotecan-induced dysarthria. J Natl Cancer Inst 2001; 93:1419-20.
4. Ceccaldi B, Kara F, Mommeja-Marin H, Begue M, Saint Blancard P, Le Marec E, et al. Dysarthrie lors de l'administration d'irinotecan. Rev Med Interne 2002;23:950-1.
5. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
6. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-21.
7. Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, et al. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 1998;41:464-8.